Skip to main content

Table 4 Cumulative resistance rates with continuous 4-year telbivudine treatment in HBeAg-positive and HBeAg-negative Taiwanese patients showing an HBV DNA decline of >5 log 10 copies/mL and ≤5 log 10 copies/mL

From: Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24

   HBeAg-positive patients (%) HBeAg-negative patients (%)
Genotypic resistance to telbivudine Year 4 43.8% 12.5%
Predictive factors at Week 24    
Undetectable/Detectable levels of HBV DNA Year 4 0%/77.8% 8.7%/100%
Achieved/Non-achieved reduction of 5 log10 copies/mL Year 1 0%/0% NA
Year 2 7.6%/75% NA
Year 3 15%/100% NA
Year 4 15%/100% NA